| Literature DB >> 8389572 |
P Dufour1, J M Lang, C Giron, B Duclos, P Haehnel, D Jaeck, J M Jung, F Oberling.
Abstract
Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium dithiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and 12 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8389572 DOI： 10.1007/bf01877380
Source DB: PubMed Journal: Biotherapy ISSN： 0921-299X